
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Click through this topline on primordial and primary CVD prevention based on the American Society of Preventive Cardiology's clinical practice statement.
A






